AndreaBozzo/ceres-open-data-index huggingface dataset:
Comparison of NSDUH Mental Health Data and Methods with Other Data Sources

This report compares adult mental health prevalence estimates generated from the 2009 National Survey on Drug Use and Health (NSDUH) with estimates of similar measures generated from other national data sources. It also describes the methodologies of the different data sources and discusses the differences in survey design and estimation that may contribute to differences among these estimates. The other data systems discussed include the 2001 to 2003 National Comorbidity Survey Replication (NCS-R), 2001 to 2002 National Epidemiologic Survey on Alcohol and Related Conditions (NESARC), 2007 Behavioral Risk Factor Surveillance System (BRFSS), 2008 National Health Interview Survey (NHIS), 2008 Medical Expenditure Panel Survey (MEPS), and 2008 Uniform Reporting System (URS).
Compound 528111: 2-Chloro-3-methyl-5-(2-methylbutyl)pyrazine

Chemical compound data from PubChem database. IUPAC Name: 2-chloro-3-methyl-5-(2-methylbutyl)pyrazine. Molecular Formula: C10H15ClN2. Molecular Weight: 198.69. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E400929-T1: [Translated] ADAPTER FOR COMMUNICATION VIA POWER SUPPLY LINES

An adapter for communicating over power line is disclosed. An adapter for communicating over power line of the present invention is comprised of a transmitting unit, comprising a power supply including a transformer, a plurality of rectifiers, and a smoother, an oscillator for oscillating a carrier frequency for signal transmission, a switching unit for switching in response to a signal transmitted from a modem, a first coil, positioned between the switching unit and the oscillator, for combining the carrier frequency and data transmitted from the switching unit and magnetizing the combined result; and a first pulse transformer comprising first and second denser electrodes, which are induced electromagnetically by the firs coil and separated mutually and electrically by means of dielectrics or insulators, including first and second lead lines respectively, each connected to the power lines for signal transmission, and a receiving unit comprising a second pulse transformer having a reverse structure to the first pulse transformer a filter for passing the carrier frequency of data among signals output from the second pulse transformer, and a data separating unit for separating transmission data between the filter and the modem.
A bovine papillomavirus-1 based vector restores the function of the low-density lipoprotein receptor in the receptor-deficient CHO-ldlA7 cell line

Background
          The rationale of using bovine papillomavirus-1 (BPV-1) derived vectors in gene therapy protocols lies in their episomal maintenance at intermediate to high copy number, and stable, high-level expression of the gene products. We constructed the BPV-1 based vector harbouring the human low-density lipoprotein receptor (LDLR) gene cDNA and tested its ability to restore the function of the LDLR in the receptor-deficient cell line CHO-ldlA7.
        
        
          Results
          The introduced vector p3.7LDL produced functionally active LDL receptors in the receptor-deficient cell line CHO-ldlA7 during the 32-week period of observation as determined by the internalisation assay with the labelled LDL particles.
        
        
          Conclusion
          Bovine papillomavirus type-1 (BPV-1)-derived vectors could be suitable for gene therapy due to their episomal maintenance at intermediate to high copy number and stable, high-level expression of the gene products. The constructed BPV-1 based vector p3.7LDL produced functionally active LDL receptors in the LDLR-deficient cell line CHO-ldlA7 during the 32-week period of observation.
          In vivo experiments should reveal, whether 1–5% transfection efficiency obtained in the current work is sufficient to bring about detectable and clinically significant lowering of the amount of circulating LDL cholesterol particles.
Compound 527845: 2,4-Dichlorobenzyl hexadecyl ether

Chemical compound data from PubChem database. IUPAC Name: 2,4-dichloro-1-(hexadecoxymethyl)benzene. Molecular Formula: C23H38Cl2O. Molecular Weight: 401.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E400831-T1: [Translated] MICROFABRICATED MIRROR DEVICE

A micro machined mirror assembly is provided that includes a micro machined top cap, mirror, and bottom cap mounted onto a ceramic substrate. The micro machined mirror is resiliently supported by a pair of T-shaped hinges and includes travel stops that limit motion of the mirror in the z-direction. The top and bottom micro machined caps also include travel stops that limit motion of the mirror in the z-direction.
NCHS - Natality Measures for Females by Hispanic Origin Subgroup: United States

This dataset includes live births, birth rates, and fertility rates by Hispanic origin of mother in the United States since 1989. 

National data on births by Hispanic origin exclude data for Louisiana, New Hampshire, and Oklahoma in 1989; New Hampshire and Oklahoma in 1990; and New Hampshire in 1991 and 1992. Birth and fertility rates for the Central and South American population includes other and unknown Hispanic. Information on reporting Hispanic origin is detailed in the Technical Appendix for the 1999 public-use natality data file (see ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/DVS/natality/Nat1999doc.pdf).
Compound 530281: Tetradecane, 6-butyl-7-ethyl

Chemical compound data from PubChem database. IUPAC Name: 6-butyl-7-ethyltetradecane. Molecular Formula: C20H42. Molecular Weight: 282.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Provisional COVID-19 Deaths by County, and Race and Hispanic Origin

Effective September 27, 2023, this dataset will no longer be updated. Similar data are accessible from wonder.cdc.gov.

County data on race and Hispanic origin is available for counties with more than 100 COVID-19 deaths. Deaths are cumulative from the week ending January 4, 2020 to the most recent reporting week, and based on county of occurrence. Data is provisional. 

Urban-rural classification is based on the 2013 National Center for Health Statistics Urban-Rural Classification Scheme for Counties (https://www.cdc.gov/nchs/data_access/urban_rural.htm).
Compound 528358: 1,2,3,5,6-Pentathiepane, 4,7-dimethyl-

Chemical compound data from PubChem database. IUPAC Name: 4,7-dimethyl-1,2,3,5,6-pentathiepane. Molecular Formula: C4H8S5. Molecular Weight: 216.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E399559-T1: [Translated] ANTIMICROBIAL PREPARATION

The present invention relates to the treatment of gastrointestinal disease and/or cancer, and a method of weight gain, via the ingestion of polymeric compositions in humans, animals or birds in need of said treatment. The invention provides methods for the treatment of cancer, the treatment and/or prevention of gastrointestinal disease and/or infection and/or diarrhoea, and a method for increasing weight gain in humans, animals or birds comprising administering to said humans, animals or birds an effective amount of a pharmaceutical or veterinary composition or feed additive, comprising an effective amount of a polymer and/or copolymer, having the repeating polymeric unit (I) wherein R is H or alkyl, usually C1 to C4, or this unit in hydrated, hemiacetal or acetal form, together with a pharmaceutically or veterinarally acceptable carrier, diluent, adjuvant, excipient and/or controlled release system. <CHEM>
NCHS - Natality Measures for Females by Race and Hispanic Origin: United States

This dataset includes live births, birth rates, and fertility rates by race of mother in the United States since 1960. 

Data availability varies by race and ethnicity groups. All birth data by race before 1980 are based on race of the child. Since 1980, birth data by race are based on race of the mother. For race, data are available for Black and White births since 1960, and for American Indians/Alaska Native and Asian/Pacific Islander births since 1980. Data on Hispanic origin are available since 1989. Teen birth rates for specific racial and ethnic categories are also available since 1989. From 2003 through 2015, the birth data by race were based on the “bridged” race categories (5). Starting in 2016, the race categories for reporting birth data changed; the new race and Hispanic origin categories are: Non-Hispanic, Single Race White; Non-Hispanic, Single Race Black; Non-Hispanic, Single Race American Indian/Alaska Native; Non-Hispanic, Single Race Asian; and, Non-Hispanic, Single Race Native Hawaiian/Pacific Islander (5,6). Birth data by the prior, “bridged” race (and Hispanic origin) categories are included through 2018 for comparison.

SOURCES

NCHS, National Vital Statistics System, birth data (see https://www.cdc.gov/nchs/births.htm); public-use data files (see https://www.cdc.gov/nchs/data_access/VitalStatsOnline.htm); and CDC WONDER (see http://wonder.cdc.gov/).

REFERENCES

1. National Office of Vital Statistics. Vital Statistics of the United States, 1950, Volume I. 1954. Available from: https://www.cdc.gov/nchs/data/vsus/vsus_1950_1.pdf.

2. Hetzel AM. U.S. vital statistics system: major activities and developments, 1950-95. National Center for Health Statistics. 1997. Available from: https://www.cdc.gov/nchs/data/misc/usvss.pdf.

3. National Center for Health Statistics. Vital Statistics of the United States, 1967, Volume I–Natality. 1969. Available from: https://www.cdc.gov/nchs/data/vsus/nat67_1.pdf.

4. Martin JA, Hamilton BE, Osterman MJK, et al. Births: Final data for 2015. National vital statistics reports; vol 66 no 1. Hyattsville, MD: National Center for Health Statistics. 2017. Available from: https://www.cdc.gov/nchs/data/nvsr/nvsr66/nvsr66_01.pdf.

5. Martin JA, Hamilton BE, Osterman MJK, Driscoll AK, Drake P. Births: Final data for 2016. National Vital Statistics Reports; vol 67 no 1. Hyattsville, MD: National Center for Health Statistics. 2018. Available from: https://www.cdc.gov/nvsr/nvsr67/nvsr67_01.pdf.

6. Martin JA, Hamilton BE, Osterman MJK, Driscoll AK, Births: Final data for 2018. National vital statistics reports; vol 68 no 13. Hyattsville, MD: National Center for Health Statistics. 2019. Available from: https://www.cdc.gov/nchs/data/nvsr/nvsr68/nvsr68_13.pdf.
Program Instruction (PI-07-07)

This Program Instruction (PI) provides instruction to tribes on the June 30, 2007 submission of the Annual Progress and Services Report (APSR) required under Title IV-B of the Act, including the submission of the CFS101, Part I (Annual Budget Request), Part II (Annual Summary of Child and Family Services), and Part III (Annual Expenditures for Title IV-B).

Metadata-only record linking to the original dataset. Open original dataset below.
Compound 526229: 1,2,3,6,9-Pentabromo-dibenzofuran

Chemical compound data from PubChem database. IUPAC Name: 1,2,3,6,9-pentabromodibenzofuran. Molecular Formula: C12H3Br5O. Molecular Weight: 562.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
2011 CMHS Uniform Reporting System (URS) Output Tables for Florida

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2011. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Patent AT-E401087-T1: [Translated] COMPOUNDS FOR PAIN TREATMENT

Compounds of the class of adenosines, represented by structural formula I, wherein R is C1-4 alkoxy, and X is H or OH, excluding 2-methoxyadenosine, are useful as analgesics, particularly in a method of preventing, treating, or ameliorating pain which comprises administering a compound of formula I to a subject in need of such prevention, treatment, or amelioration.
Compound 525697: p-Methoxybenzylidene-(3-methylphenyl)-amine

Chemical compound data from PubChem database. IUPAC Name: 1-(4-methoxyphenyl)-N-(3-methylphenyl)methanimine. Molecular Formula: C15H15NO. Molecular Weight: 225.28. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Clinical features of culture-proven

Objective
          This retrospective chart review describes the epidemiology and clinical features of 40 patients with culture-proven Mycoplasma pneumoniae infections at King Abdulaziz University Hospital, Jeddah, Saudi Arabia.
        
        
          Methods
          Patients with positive M. pneumoniae cultures from respiratory specimens from January 1997 through December 1998 were identified through the Microbiology records. Charts of patients were reviewed.
        
        
          Results
          40 patients were identified, 33 (82.5%) of whom required admission. Most infections (92.5%) were community-acquired. The infection affected all age groups but was most common in infants (32.5%) and pre-school children (22.5%). It occurred year-round but was most common in the fall (35%) and spring (30%). More than three-quarters of patients (77.5%) had comorbidities. Twenty-four isolates (60%) were associated with pneumonia, 14 (35%) with upper respiratory tract infections, and 2 (5%) with bronchiolitis. Cough (82.5%), fever (75%), and malaise (58.8%) were the most common symptoms, and crepitations (60%), and wheezes (40%) were the most common signs. Most patients with pneumonia had crepitations (79.2%) but only 25% had bronchial breathing. Immunocompromised patients were more likely than non-immunocompromised patients to present with pneumonia (8/9 versus 16/31, P = 0.05). Of the 24 patients with pneumonia, 14 (58.3%) had uneventful recovery, 4 (16.7%) recovered following some complications, 3 (12.5%) died because of M pneumoniae infection, and 3 (12.5%) died due to underlying comorbidities. The 3 patients who died of M pneumoniae pneumonia had other comorbidities.
        
        
          Conclusion
          our results were similar to published data except for the finding that infections were more common in infants and preschool children and that the mortality rate of pneumonia in patients with comorbidities was high.
Midwest (MW)

This report presents the Midwest\'s (e.g., combines Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin) estimates for 25 measures of substance use and mental health based on the combined 2009 and 2010 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Resuts are provided for the Midwest for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.
Table 13. 2011-2012 NSDUH Tobacco Product Use in the Past Month, by Age Group and State

Table 13. Tobacco Product Use in the Past Month, by Age Group and State: Percentages, Annual Averages Based on 2011 and 2012 NSDUHs. Results are provided by State and for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.
2013 NSDUH Miscellaneous Tables (Standard Errors and P Values) - 6.1 to 6.107

These detailed tables present the standard errors for the totals and prevalence estimates of the number of days and types of substance use, poly-drug use, nicotine dependence, substance dependence by age of first use, source of substances, social context of substance use, and drunk/drugged driving from the 2013 National Survey on Drug Use and Health (NSDUH). Substances examined include illicit drugs, marijuana, cocaine, heroin, hallucinogens, inhalants, and the nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, and sedatives, and alcohol. Standard errors are provided for totals and prevalence estimates of lifetime, past year, and past month use by age group, gender, race/ethnicity, education level, employment status, geographic area, pregnancy status, college enrollment status, and probation/parole status. Comparisons are made between 2013 and 2012.
Compound 528064: tert-Butyl(dimethyl)silyl 1-[tert-butyl(dimethyl)silyl]-2-pyrrolidinecarboxylate

Chemical compound data from PubChem database. IUPAC Name: [tert-butyl(dimethyl)silyl] 1-[tert-butyl(dimethyl)silyl]pyrrolidine-2-carboxylate. Molecular Formula: C17H37NO2Si2. Molecular Weight: 343.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
A simple method for statistical analysis of intensity differences in microarray-derived gene expression data

Background
          Microarray experiments offer a potent solution to the problem of making and comparing large numbers of gene expression measurements either in different cell types or in the same cell type under different conditions. Inferences about the biological relevance of observed changes in expression depend on the statistical significance of the changes. In lieu of many replicates with which to determine accurate intensity means and variances, reliable estimates of statistical significance remain problematic. Without such estimates, overly conservative choices for significance must be enforced.
        
        
          Results
          A simple statistical method for estimating variances from microarray control data which does not require multiple replicates is presented. Comparison of datasets from two commercial entities using this difference-averaging method demonstrates that the standard deviation of the signal scales at a level intermediate between the signal intensity and its square root. Application of the method to a dataset related to the β-catenin pathway yields a larger number of biologically reasonable genes whose expression is altered than the ratio method.
        
        
          Conclusions
          The difference-averaging method enables determination of variances as a function of signal intensities by averaging over the entire dataset. The method also provides a platform-independent view of important statistical properties of microarray data.
Permanency Innovations Initiative (PII) Training and Technical Assistance Project Contractor Profile

The PII-TTAP team, led by JBS International, Inc., provides training and technical assistance to support the PII Grantees in better meeting the needs of children and families by developing/adapting, implementing, and scaling up interventions in child welfare (both evidence-supported and developmental). PII-TTAP accomplishes this goal by providing innovative yet practical training and technical assistance; building capacity for implementation within PII Grantee organizations through knowledge dissemination; developing tools for effective application and transfer of implementation best practices; and actively coordinating and collaborating in implementation and evaluation activities.

Metadata-only record linking to the original dataset. Open original dataset below.
Protocol of a prospective cohort study of the effect of different methods of drainage of neuropathic bladder on occurrence of symptomatic urinary infection, and adverse events related to the urinary drainage system in spinal cord injury patients

Background
          To present a protocol of a prospective, cohort study in which four groups of spinal cord injury (SCI) patients will participate. (Patients with indwelling urethral catheter; patients who perform intermittent catheterisation without wearing a penile sheath; patients who perform intermittent catheterisation and wear penile sheath as well; and patients with penile sheath drainage).
        
        
          Objectives
          (1) What is the incidence of symptomatic urinary infection in men with spinal cord injury who use different types of bladder drainage? (2) Which are predisposing factors for the occurrence of symptomatic urinary infection in men with spinal cord injury who practise different methods of bladder drainage? (3) What is the incidence of catheter and urinary drainage system-related adverse events in the four groups of SCI patients?
        
        
          Patients
          The criteria for inclusion are as follow: (1) Male patients with neuropathic bladder due to spinal cord injury, who are registered with the Regional Spinal Injuries Centre, Southport, England. (2) Age: 18 years or above. (3) Patients who are willing to give informed consent for participation in the study. (4) Patients willing to be contacted every two weeks by a staff of the spinal unit for 36 months. (5) Patients who are willing to maintain an accurate record of adverse events related to urinary catheter and urinary drainage system and predisposing factors for the occurrence of symptomatic urinary infection. (6) Patients, who are stabilised in a particular method of bladder drainage, and therefore, unlikely to make a permanent change in the method of bladder drainage (e.g. from penile sheath drainage to the use of long-term indwelling catheter) during a foreseeable future.
        
        
          Methods
          The participants will be observed for a period of 36 months. A staff of the spinal injuries unit will contact the participants by telephone every two weeks on a mutually agreed day and time. The information obtained during this standardised telephonic interview conducted once in two weeks will be entered in a database. When a participant develops symptom(s) suggestive of urinary infection, he will undergo urine and blood tests, and imaging studies of the urinary tract.
        
        
          Conclusion
          This study will provide information regarding the occurrence of symptomatic urinary infection, predisposing factors for development of urinary infection, and adverse events related to urinary catheter and urinary drainage system in SCI patients using different methods of bladder drainage.
Phosphoinositide 3-kinase: a critical signalling event in pulmonary cells

Phosphoinositide 3-kinases (PI-3Ks) are enzymes that generate lipid second messenger molecules, resulting in the activation of multiple intracellular signalling cascades. These events regulate a broad array of cellular responses including survival, activation, differentiation and proliferation and are now recognised to have a key role in a number of physiological and pathophysiological processes in the lung. PI-3Ks contribute to the pathogenesis of asthma by influencing the proliferation of airways smooth muscle and the recruitment of eosinophils, and affect the balance between the harmful and protective responses in pulmonary inflammation and infection by the modulation of granulocyte recruitment, activation and apoptosis. In addition they also seem to exert a critical influence on the malignant phenotype of small cell lung cancer. PI-3K isoforms and their downstream targets thus provide novel therapeutic targets for intervention in a broad spectrum of respiratory diseases.